Skip to main content
Clinical Trials/NCT05133388
NCT05133388RecruitingNot Applicable

The Prevelence of HBB c.93-21 G-A Gene Mutation in Suspected Cases of β Thalassemia in Assiut University Hospitals.

Assiut University1 site in 1 country150 target enrollmentStarted: January 30, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
150
Locations
1
Primary Endpoint
Introduction of arms pcr in diagnosis .

Study Overview

Brief Summary

  • To design an amplification-refractory mutation system (ARMS) for the DNA diagnosis of the IVS I-110 (G>A) [HBB:c.93-21G˃A] mutation.
  • To detect the prevelence of the mutation among Assiut University Hospital patients.
  • Phenotype/genotype correlation of the mutation.

Detailed Description

  • The β-thalassaemias result from over 300 gene mutations (Kurtoğlu A,et al 2016)
  • These mutations are regionally specific and the spectrum of mutations has been determined for most at-risk populations. The strategy for identifying β-thalassaemia mutations is usually based on knowledge of the common mutations in the ethnic group of the individual being screened (Old JM, 2007).

The β globin gene mutation [HBB:c.93-21G˃A] or IVS I-110 (G>A) is the most common β globin gene mutation in the Mediterranean region (Old JM, 2007). . There is no consensus about the % of the mutation among β thalassemic patients in Egypt [has been reported (25.8%) by El-Gawhary et al. 2007, (33.75%) by Soliman et al. 2010, (48%) by El-Shanshory et al. 2014, (22%) by Elmezayen et al. 2015 and (34%) by Elhalfawy et al. 2017].

According to the HbVar site, it represents 33% of the β globin gene mutations in the Egyptians. 28.5% according to Henderson S ,et al 2009 .

  • The mechanism of this mutation depends on formation of a new splicing site resulting in 80% abnormal spliced mRNA and 20% normal mRNA .
  • The molecular characterization of the globin gene mutation is necessary for definite diagnosis, genetic counseling, and in prenatal diagnosis.
  • The amplification-refractory mutation system (ARMS) is a simple method for detecting any mutation involving single base changes or small deletions.
  • The DNA is analyzed after amplification by PCR for Detection of point mutation IVS I-110 (G>A) by Using primer pairs that only amplify individual alleles.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Retrospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • β thalassemia (suspected & clinically diagnosed cases)

Exclusion Criteria

  • Iron deficiency anaemia, anaemia of chronic disease, types of haemolytic anaemias other than thalassemia, other types of thalassemia and Hb variants.

Outcomes

Primary Outcomes

Introduction of arms pcr in diagnosis .

Time Frame: 2 years

To introduce the ARMS PCR as a cheap and simple DNA diagnostic tool for any point mutation

Database initation .

Time Frame: 2 years

Initiating database of haemoglobinopathesis by registering data.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Amira Saber Hamed Ahmed

ASHAhmed

Assiut University

Study Sites (1)

Loading locations...

Similar Trials